Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 15/20 | 0.48 |
| ▸ | CDK4 | P11802 | 6/20 | 0.48 |
| ▸ | CDK1 | P06493 | 2/20 | 0.42 |
| ▸ | IKBKB | O14920 | 4/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6443063 | 0.84 | CDK2 (0.58) | CDK2CDK4CDK1IKBKBSYK | |
| SCHEMBL6604567 | 0.79 | CDK2 (0.64) | CDK2CDK4CDK1IKBKBSYK | |
| SCHEMBL6384379 | 0.78 | CDK2 (0.56) | CDK2CDK4CDK1IKBKBSYK | |
| SCHEMBL6606156 | 0.77 | CDK2 (0.52) | CDK2CDK4CDK1IKBKB | |
| SCHEMBL6608604 | 0.77 | CDK2 (0.56) | CDK2CDK4CDK1IKBKBSYK | |
| SCHEMBL5915798 | 0.75 | CDK2 (0.72) | CDK2CDK4CDK1 | |
| SCHEMBL6606019 | 0.74 | CDK2 (0.64) | CDK2CDK4CDK1IKBKBSYK | |
| SCHEMBL6382088 | 0.74 | CDK2 (0.61) | CDK2CDK4CDK1SYK | |
| SCHEMBL6603828 | 0.73 | CDK2 (0.45) | CDK2CDK4CDK1IKBKB | |
| SCHEMBL5783470 | 0.73 | CDK2 (0.57) | CDK2CDK4CDK1IKBKBSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256311-A1 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256311-A1 | Pyrimidine compounds | TYMP, TYMS, CCNT1 | CDK2 24/4885CDK4 48/4885CDK1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.